Which company's product is Durvalumab?

Durvalumab/Infinifer (Durvalumab) is an innovative immune checkpoint inhibitor developed and produced by AstraZeneca AB, a world-renowned pharmaceutical company. AstraZeneca is a multinational pharmaceutical company headquartered in the United Kingdom with extensive R&D experience and international clinical trial layout in the fields of oncology and immunotherapy. As an original drug manufacturer, AstraZeneca is responsible for the entire process management from preclinical research, clinical trials to global registration and marketing, while ensuring the quality standards and long-term supply of drugs.

Durvalumab belongs to the class of PD-L1 monoclonal antibodies. By blocking the binding of PD-L1 on the surface of tumor cells to the PD-1 receptor of T cells, it relieves the tumor's suppression of the immune system, thereby activating T cells to attack the tumor. As AstraZeneca's original research product, Infineon is approved in many countries around the world. Its main indications include locally advanced unresectable small cell lung cancer, non-small cell lung cancer (NSCLC) and certain locally advanced or metastatic urothelial cancers. The original research status means that the production, quality control, clinical research and regulatory data of the drug are strictly controlled by AstraZeneca to ensure the stability, safety and efficacy of the drug.

In addition, AstraZeneca has developed detailed patient management guidelines for durvalumab, covering administration methods, dosage regimens, follow-up monitoring and adverse reaction management, to help doctors use the drug rationally in clinical practice. Through ongoing global clinical research, AstraZeneca continues to update drug descriptions and indication expansions to provide patients with the latest treatment options. For patients, choosing original drugs not only means obtaining therapeutic effects that have been rigorously clinically verified, but also guarantees medication safety and long-term compliance to a certain extent.

Reference materials:https://www.imfinzi.com/